Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 7/20 | 0.60 |
| ▸ | TK1 | P04183 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | EDNRA | P25101 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | HBB | P68871 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | VCP | P55072 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | HPRT1 | P00492 | 8/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7688918 | 0.87 | PNP (0.61) | PNPTK1BLMUSP2TSHR | |
| SCHEMBL27709434 | 0.86 | PNP (0.60) | PNPTK1BLMUSP2TSHR | |
| SCHEMBL9960816 | 0.83 | PNP (0.68) | PNPTK1BLMUSP2TSHR | |
| SCHEMBL29286376 | 0.83 | TK1 (0.76) | PNPTK1BLMUSP2TSHR | |
| SCHEMBL10506454 | 0.82 | TK1 (0.63) | PNPTK1BLMUSP2TSHR | |
| SCHEMBL5324092 | 0.82 | PNP (0.69) | PNPTK1BLMUSP2TSHR | |
| SCHEMBL18521979 | 0.82 | PNP (0.66) | PNPTK1BLMUSP2TSHR | |
| SCHEMBL13397350 | 0.81 | TK1 (0.72) | PNPTK1BLMUSP2TSHR | |
| SCHEMBL874736 | 0.81 | PNP (0.64) | PNPTK1BLMUSP2TSHR | |
| SCHEMBL9806969 | 0.79 | TK1 (0.71) | PNPTK1BLMUSP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799524-B2 | Substrates for O6-alkylguanina-DNA alkyltransferase | Ecole Polytechnique Ferdeale de Lausanne (CH) | 2010-09-21 | — | — | US | disclosed |
| US-20060024775-A1 | Substrates for o6-alkylguanina-dna alkyltransferase | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL). (CH) | 2006-02-02 | — | — | US | disclosed |
| CN-1720332-A | O6Substrates for -alkylguanine-DNA alkyltransferases | ECOLE POLYTECH (CH) | 2006-01-11 | — | — | CN | disclosed |
| EP-1017394-B1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER REC TECH LTD (GB) | 2005-12-07 | — | — | EP | disclosed |
| EP-1546371-A1 | SUBSTRATES FOR O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004031405-A1 | SUBSTRATES FOR O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2004-04-15 | — | — | WO | disclosed |
| US-6303618-B1 | ADMINISTERING PURINE COMPOUND WHICH INHIBITS CYCLIC DEPENDENT KINASE ACTIVITY FOR THERAPY OF TUMOR OR OTHER CELL PROLIFERATION DISORDER | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2001-10-16 | — | — | US | disclosed |
| EP-1017394-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999002162-A9 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RES CAMPAIGN TECH (GB) | 1999-07-29 | — | — | WO | disclosed |
| WO-1999002162-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060024775-A1 | Substrates for o6-alkylguanina-dna alkyltransferase | AGT, OGG1, NUDT1 | PNP 176/4885TK1 20/4885BLM 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.